EGFR and lung adenocarcinoma: A total of 10,046 patients with EGFR-mutant advanced lung adenocarcinoma initiated first-line EGFR-TKI therapy with 3,695 patients who received gefitinib, 3,310 who received erlotinib and 3,041 who received afatinib (Supplementary Figure S1 in Supplement).